These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

680 related articles for article (PubMed ID: 29073957)

  • 1. Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond.
    Libby P
    J Am Coll Cardiol; 2017 Oct; 70(18):2278-2289. PubMed ID: 29073957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week.
    Ridker PM
    J Am Coll Cardiol; 2018 Dec; 72(25):3320-3331. PubMed ID: 30415883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection.
    Ridker PM
    Circ Res; 2016 Jan; 118(1):145-56. PubMed ID: 26837745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Thuren T; Zalewski A; Libby P
    Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice.
    Tuñón J; Bäck M; Badimón L; Bochaton-Piallat ML; Cariou B; Daemen MJ; Egido J; Evans PC; Francis SE; Ketelhuth DF; Lutgens E; Matter CM; Monaco C; Steffens S; Stroes E; Vindis C; Weber C; Hoefer IE;
    Eur J Prev Cardiol; 2018 Jun; 25(9):948-955. PubMed ID: 29759006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical roles of inflammation in atherosclerosis.
    Moriya J
    J Cardiol; 2019 Jan; 73(1):22-27. PubMed ID: 29907363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CANTOS - is selective targeting of inflammation in atherosclerosis enough?
    Misra DP; Agarwal V
    J R Coll Physicians Edinb; 2018 Sep; 48(3):246-247. PubMed ID: 30191914
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial.
    Everett BM; MacFadyen JG; Thuren T; Libby P; Glynn RJ; Ridker PM
    J Am Coll Cardiol; 2020 Oct; 76(14):1660-1670. PubMed ID: 33004131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atherosclerosis: perspectives of anti-inflammatory therapy.
    Nasonov EL; Popkova TV
    Ter Arkh; 2018 May; 90(5):4-12. PubMed ID: 30701884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis.
    Khan R; Rheaume E; Tardif JC
    Curr Atheroscler Rep; 2018 Sep; 20(11):53. PubMed ID: 30219977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inflammation and atherosclerosis – last piece of the puzzle has fallen into place].
    Jonasson L; Hansson G
    Lakartidningen; 2017 Oct; 114():. PubMed ID: 29292899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of interleukin 1β inhibition in cardiovascular disease.
    Qamar A; Rader DJ
    Curr Opin Lipidol; 2012 Dec; 23(6):548-53. PubMed ID: 23069985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting IL-1β in the Treatment of Atherosclerosis.
    Mai W; Liao Y
    Front Immunol; 2020; 11():589654. PubMed ID: 33362770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis.
    Vromman A; Ruvkun V; Shvartz E; Wojtkiewicz G; Santos Masson G; Tesmenitsky Y; Folco E; Gram H; Nahrendorf M; Swirski FK; Sukhova GK; Libby P
    Eur Heart J; 2019 Aug; 40(30):2482-2491. PubMed ID: 30698710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Utility of Anti-Inflammatory Agents in Cardiovascular Disease: A Novel Perspective on the Treatment of Atherosclerosis.
    Kottoor SJ; Arora RR
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):483-493. PubMed ID: 29783850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory therapy for atherosclerosis: interpreting divergent results from the CANTOS and CIRT clinical trials.
    Ridker PM
    J Intern Med; 2019 May; 285(5):503-509. PubMed ID: 30472762
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical implication and association between local and systemic levels of interleukin-1β and interleukin-10 in patients with coronary artery disease].
    Yan HB; Li WZ; Zhao HJ; Song L; Zheng B; Zhou P; Liu C
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Feb; 39(2):142-6. PubMed ID: 21426749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new strategy for the treatment of atherothrombosis - inhibition of inflammation.
    Slíva J; Charalambous C; Bultas J; Karetová D
    Physiol Res; 2019 Nov; 68(Suppl 1):S17-S30. PubMed ID: 31755287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 1β: a proinflammatory target for preventing atherosclerotic heart disease.
    McCarty S; Frishman W
    Cardiol Rev; 2014; 22(4):176-81. PubMed ID: 24618930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease.
    Moreira DM; da Silva RL; Vieira JL; Fattah T; Lueneberg ME; Gottschall CA
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):1-11. PubMed ID: 25369900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.